Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Tissue Regenix Group plc TSSNF OTC

Other OTC • Healthcare • Biotechnology • GB • USD

SharesGrow Score
44/100
1/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Tissue Regenix Group plc (TSSNF) is a Biotechnology company in the Healthcare sector, currently trading at $0.01. It has a SharesGrow Score of 41/100, indicating a mixed investment profile with 1 out of 7 criteria passed.

Financials: revenue is $29M, +28%/yr average growth. Net income is $713,000 (loss), growing at +39.1%/yr. Net profit margin is -2.5% (negative). Gross margin is 47.5% (+8.3 pp trend).

Balance sheet: total debt is $10M against $30M equity (Debt-to-Equity (D/E) ratio 0.35, conservative). Current ratio is 3.46 (strong liquidity). Debt-to-assets is 23.1%. Total assets: $45M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 100/100 (Pass), Past 0/100 (Fail), Health 67/100 (Partial), Moat 43/100 (Fail), Future ?/100 (Fail), Income 10/100 (Fail).

TSSNF SharesGrow Score Overview

55/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 100/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 43/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — TSSNF

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✓
GROWTH Pass
100/100
TSSNF: +28%/yr revenue is, +39.1%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet TSSNF: Debt-to-Equity (D/E) ratio 0.35 (conservative), Current ratio is 3.46 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
43/100
TSSNF: Gross margin is 47.5% (+8.3 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 43/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
✗
INCOME Fail
10/100
TSSNF: Net profit margin is -2.5%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.005-0.005
Volume31.28K
Beta (1Y)1.43
Share Statistics
EPS (TTM)-0.01
Shares Outstanding$70.6M
IPO Date2016-11-14
Employees79
CEODaniel R. Lee
Financial Highlights & Ratios
Revenue (TTM)$28.65M
Gross Profit$13.62M
EBITDA$1.36M
Net Income$-713K
Operating Income$349K
Total Cash$1.87M
Total Debt$10.47M
Net Debt$8.6M
Total Assets$45.35M
Price / Earnings (P/E)-0.5
Analyst Forecast
Company Info
CountryGB
ExchangeOther OTC
CurrencyUSD

Price Chart

Track all markets on TradingView
TSSNF
Tissue Regenix Group plc ↗  ·  Other OTC
Healthcare • Biotechnology

People Also View

LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
 RHHBF
RHHBF
Roche Holding AG
$418.50
+1.82%
 RHHBY
RHHBY
Roche Holding AG
$51.02
+0.65%
 AZN
AZN
AstraZeneca PLC
$204.38
+1.06%
 NVSEF
NVSEF
Novartis AG
$156.48
+0.00%
 MRK
MRK
Merck & Co., Inc.
$119.96
-0.16%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message